… ProQR Announces Additional Sepofarsen Illuminate Trial … top-line announcement in February 2022 that Illuminate , ProQR’s pivotal Phase 2/3 trial of sepofarsen in CEP290 … scheme by the EMA. About Usher s yndrome t ype 2 a and r etinitis p igmentosa Usher syndrome is the leading cause of …
… ProQR and Rett Syndrome Research Trust Join Forces with … variant that causes Rett syndrome Collaboration expands ProQR’s commitment to advance the development of therapies … (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through …
… ProQR to Focus Exclusively on Axiomer RNA-editing Technology … & CAMBRIDGE, Mass., Aug. 11, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a … scheme by the EMA. About Usher s yndrome t ype 2 a and r etinitis p igmentosa Usher syndrome is the leading cause of …
… ProQR Announces Presentation on its Axiomer™ RNA Editing … (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through … Development” This presentation will provide an overview of ProQR’s proprietary ADAR-mediated Axiomer RNA editing …
… ProQR Announces Annual General Meeting of Shareholders to be … (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through … be made available in the “Investors & Media” section of ProQR’s website ( www.proqr.com ) under “Financials and …
Substantial progress in 2019 with final data from Phase 1/2 trial of sepofarsen for Leber’s congenital amaurosis 10 showing rapid, significant and durable improvements in vision; Phase 2/3 pivotal trial Illuminate initiated with data expected in H1 2021Phase 1/2 St
… ProQR Announces Webcast of Presentation at Upcoming HC … on demand from the “Investors & Media” section of ProQR’s website ( www.proqr.com ) under ‘Events’, beginning March 9, 2021. …
… ProQR Announces Recent Progress and Financial Results for the … & CAMBRIDGE, Mass., Nov. 06, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a … said Daniel A. de Boer, chief executive officer of ProQR. “In October we announced that LCA10 patients …